AnGes, Inc. Logo

AnGes, Inc.

Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnGes, Inc., founded in 1999, is a biopharmaceutical company dedicated to the research and development of gene-based medicines. The company focuses on becoming a global leader in genetic pharmaceuticals by developing innovative treatments that harness the power of genes. Its core pipeline includes Hepatocyte Growth Factor (HGF) gene therapy products for blood vessel regeneration, DNA vaccines based on plasmid DNA technology, and NF-kB decoy oligonucleotides. AnGes actively engages in clinical studies and forms global alliances and manufacturing collaborations to advance its therapeutic programs and make novel treatments accessible to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 244.5 KB
2025-08-13 06:50
Interim Report
確認書
Japanese 8.9 KB
2025-08-13 04:19
Interim Report
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese 488.0 KB
2025-03-31 04:52
Post-Annual General Meeting Information
臨時報告書
Japanese 25.5 KB
2025-03-31 03:22
Governance Information
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese 23.7 KB
2025-03-31 03:18
Registration Form
確認書
Japanese 8.9 KB
2025-03-31 03:17
Registration Form
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2024-09-03 06:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 203.2 KB
2024-08-30 09:06
Registration Form
有価証券届出書(参照方式)
Japanese 381.2 KB
2024-08-14 02:28
Interim Report
確認書
Japanese 8.9 KB
2024-08-14 02:27
Interim Report
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese 725.7 KB
2024-05-14 02:27
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-05-14 02:25
Quarterly Report
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese 457.7 KB
2024-03-29 01:45
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2024-03-29 01:43
Governance Information
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese 23.6 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Upstream Bio, Inc. Logo
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
UroGen Pharma Ltd. Logo
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France
ALVAL
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
Vanda Pharmaceuticals Inc. Logo
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990
Vaxcyte, Inc. Logo
A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.
United States of America
PCVX
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom
VLG
Ventyx Biosciences, Inc. Logo
Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.
United States of America
VTYX
Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM

Talk to a Data Expert

Have a question? We'll get back to you promptly.